127 related articles for article (PubMed ID: 18480090)
1. Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.
Rogers J; Schoepp RJ; Schröder O; Clements TL; Holland TF; Li JQ; Li J; Lewis LM; Dirmeier RP; Frey GJ; Tan X; Wong K; Woodnutt G; Keller M; Reed DS; Kimmel BE; Tozer EC
Protein Eng Des Sel; 2008 Aug; 21(8):495-505. PubMed ID: 18480090
[TBL] [Abstract][Full Text] [Related]
2. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
5. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
[TBL] [Abstract][Full Text] [Related]
6. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
8. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
[TBL] [Abstract][Full Text] [Related]
9. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
10. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
12. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a novel vesicular stomatitis virus pseudotype-based assay for detection of neutralizing antibody responses to SARS-CoV.
Fukushi S; Mizutani T; Saijo M; Kurane I; Taguchi F; Tashiro M; Morikawa S
J Med Virol; 2006 Dec; 78(12):1509-12. PubMed ID: 17063504
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
[TBL] [Abstract][Full Text] [Related]
15. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
16. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR; Bhatnagar PK; Das D
J Pharm Pharm Sci; 2008 Apr; 11(2):1s-13s. PubMed ID: 19203466
[TBL] [Abstract][Full Text] [Related]
18. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
Pang H; Liu Y; Han X; Xu Y; Jiang F; Wu D; Kong X; Bartlam M; Rao Z
J Gen Virol; 2004 Oct; 85(Pt 10):3109-3113. PubMed ID: 15448374
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats.
Liu RY; Wu LZ; Huang BJ; Huang JL; Zhang YL; Ke ML; Wang JM; Tan WP; Zhang RH; Chen HK; Zeng YX; Huang W
Virus Res; 2005 Sep; 112(1-2):24-31. PubMed ID: 16022898
[TBL] [Abstract][Full Text] [Related]
20. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV).
Wang S; Sakhatskyy P; Chou TH; Lu S
J Immunol Methods; 2005 Jun; 301(1-2):21-30. PubMed ID: 15894326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
